Stocks and Investing
Stocks and Investing
Mon, October 29, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, October 26, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Upgraded (VRTX) to Strong Buy and Held Target at $220 on, Oct 26th, 2018
Andrew Fein of HC Wainwright & Co., Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Strong Buy and Held Target at $220 on, Oct 26th, 2018.
Andrew has made no other calls on VRTX in the last 4 months.
There are 5 other peers that have a rating on VRTX. Out of the 5 peers that are also analyzing VRTX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Carter Gould of "UBS" Maintained at Hold with Increased Target to $188 on, Thursday, July 26th, 2018
These are the ratings of the 4 analyists that currently disagree with Andrew
- Christopher Raymond of "Raymond James" Maintained at Buy with Decreased Target to $201 on, Thursday, October 25th, 2018
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $192 on, Thursday, October 25th, 2018
- Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $206 on, Monday, July 30th, 2018
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $211 on, Thursday, July 26th, 2018